Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 1.00 |
| ▸ | AGXT | P21549 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1520090 | 0.97 | IDO1 (1.00) | IDO1AGXTCYP3A4 | |
| SCHEMBL438248 | 0.84 | IDO1 (0.78) | IDO1AGXTCYP3A4 | |
| Hydrochloric Acid SCHEMBL17289457 | 0.77 | IDO1 (0.65) | IDO1AGXTCYP3A4 | |
| SCHEMBL7888039 | 0.76 | IDO1 (0.64) | IDO1AGXT | |
| Hydrochloric Acid SCHEMBL23455644 | 0.75 | IDO1 (1.00) | IDO1AGXTCYP3A4 | |
| Hydrochloric Acid SCHEMBL1714873 | 0.75 | AGXT (1.00) | IDO1AGXTCYP3A4 | |
| Hydrochloric Acid SCHEMBL660379 | 0.75 | IDO1 (1.00) | IDO1AGXT | |
| Hydrochloric Acid SCHEMBL1715505 | 0.75 | IDO1 (0.70) | IDO1AGXTCYP3A4 | |
| Hydrochloric Acid SCHEMBL1715739 | 0.75 | IDO1 (1.00) | IDO1AGXTCYP3A4 | |
| Hydroxyamine SCHEMBL8923579 | 0.75 | IDO1 (0.62) | IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119667059-A | Method for detecting low molecular aldehydes in white spirit | 劲牌有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119667059-A | Method for detecting low molecular aldehydes in white spirit | 劲牌有限公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2024163405-A1 | BORON CONTAINING COMPOUNDS AND THEIR USES | 5METIS, INC. (US) | 2024-08-08 | — | — | WO | disclosed |
| CN-117924277-A | Oxime ether compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20210169911-A1 | PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-10 | — | — | US | disclosed |
| CN-108440446-B | Benzothiazine-4-ketone compound containing oximino fragment and preparation method thereof | 中国医学科学院医药生物技术研究所 | 2020-05-15 | — | — | CN | disclosed |
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-02-04 | — | — | US | disclosed |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-06-06 | — | — | US | disclosed |
| US-8536157-B2 | Non-steroidal compounds | THE UNIVERSITY OF MELBOURNE (AU) | 2013-09-17 | — | — | US | disclosed |
| CN-102584711-A | 3-benzyloxy-hydantoin with antineoplastic activity | UNIV NANCHANG | 2012-07-18 | — | — | CN | disclosed |
| EP-0111955-A1 | Prostaglandin intermediates | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-06-27 | — | — | EP | disclosed |
| EP-0045118-B1 | INTERMEDIATES FOR THE SYNTHESIS OF BICYCLO (2,2,1) HEPTANES AND BICYCLO (2,2,1) HEPT-2Z-ENES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-04-04 | — | — | EP | disclosed |
| US-4430345-A | 6-ALDOXIME OR KETOXIME BICYCLO(2,2,1)-NEPTANES FOR TREATMENT OF THROMBOSIS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-02-07 | — | — | US | disclosed |
| EP-0013607-B1 | SUBSTITUTED BICYCLO (2,2,1)HEPTANES AND BICYCLO (2,2,1) HEPT-2-ENES AND THEIR PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-03-23 | — | — | EP | disclosed |
| US-4368332-A | NORBORNANE DERIVATIVES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-01-11 | — | — | US | disclosed |
| EP-0045118-A2 | Intermediates for the synthesis of bicyclo (2,2,1) heptanes and bicyclo (2,2,1) hept-2Z-enes | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1982-02-03 | — | — | EP | disclosed |
| WO-1982000142-A1 | PROSTAGLANDINS | JONES R | 1982-01-21 | — | — | WO | disclosed |
| EP-0043292-A2 | Prostaglandins | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1982-01-06 | — | — | EP | disclosed |
| EP-0013607-A1 | Substituted bicyclo (2,2,1)heptanes and bicyclo (2,2,1) hept-2-enes and their pharmaceutical compositions | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1980-07-23 | — | — | EP | disclosed |
| WO-1980001381-A1 | SUBSTITUTED BICYCLO (2,2,1) HEPTANES AND HEPT-2-ENES | JONES R (GB) | 1980-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | RNASEH1, RNASE1, RNASEL | IDO1 115/4885AGXT 768/4885CYP3A4 915/4885 |
| US-20210169911-A1 | PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORS | NUDT1, NTPCR, NT5C2 | IDO1 375/4885AGXT 1671/4885CYP3A4 3981/4885 |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | RNASEH1, RNASE1, RNASEL | IDO1 115/4885AGXT 768/4885CYP3A4 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.